The mission of SWOG is to improve the practice of medicine in detecting, preventing, and treating cancer. The SWOG Cancer Control Research Base supports this mission through the development, conduct, analysis, and publication of clinical trials in cancer treatment, control and prevention as well as associated research. On average SWOG manages 50 on-going protocols and recruits 5-15,000 patients or subjects yearly to its trials. Under the direction of the Group Chair, the Associate Chair for Cancer Control and Prevention sets the scientific agenda for cancer control and prevention (CCP) within SWOG, which is implemented within five CCP committees;Prevention, Molecular Epidemiology, Cancer Survivorship, Symptom Management and Quality of Life, and Outcomes and Comparative Effectiveness. Often in partnership one of the eight SWOG disease oriented committees (Breast, Gastrointestinal, Genitourinary, Leukemia, Lung, Lymphoma, Melanoma, and Myeloma). The investigators within CCP develop and conduct research that is relevant, innovative and translatable. Additionally, SWOG manages and supports a large set of biorepositories and the infrastructure to provide these clinically annotated specimens to the research community at large. Further, SWOG will provide a unique resource to the research community through the development of a Cancer Comparative Effectiveness Research Center (CCERC) to provide facilitate the prioritization, design, implementation and translation of prospective comparative effectiveness trials within the NCI cooperative group network. The CCERC will become a model infrastructure within the NIH for leveraging burgeoning opportunities in comparative effectiveness research, including the new Patient Centered Outcomes Research Institute (PCORI) and commercial health insurer's movement towards coverage with evidence development funding models. The SWOG Research Base is partnered with 26 Community Clinical Oncology Programs (CCOP) or Minority Based CCOP and approximately 35% of its total accrual comes from the CCOP program. CCOP physicians play a leadership role within the group structure.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Minasian, Lori M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Tang, Li; Platek, Mary E; Yao, Song et al. (2018) Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 39:125-133
Klein, Alison P; Wolpin, Brian M; Risch, Harvey A et al. (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556
Cook, Michael B; Barnett, Matthew J; Bock, Cathryn H et al. (2018) Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium. Gut :
Hershman, Dawn L; Unger, Joseph M; Greenlee, Heather et al. (2018) Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA 320:167-176
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Lance, Peter; Alberts, David S; Thompson, Patricia A et al. (2017) Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention. Cancer Prev Res (Phila) 10:45-54
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Miles, Fayth L; Goodman, Phyllis J; Tangen, Catherine et al. (2017) Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients 9:
Unger, Joseph M; Griffin, Katherine; Donaldson, Gary W et al. (2017) Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes 2:27
Platz, Elizabeth A; Kulac, Ibrahim; Barber, John R et al. (2017) A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev 26:1549-1557

Showing the most recent 10 out of 368 publications